Neuro-Oncology News

To advance health equity, it is time to normalize the collection of sexual orientation and gender identity (SOGI) data in clinical practice and in health services research.

Standard cancer care may fail to adequately address the needs of LGBTQ+ individuals, who face substantial disparities in access to screening, treatment and outcomes.

People with MS had lower overall and cancer-specific survival soon after colorectal cancer diagnosis compared with those without MS, according to results of a retrospective matched cohort study published in Neurology.

Inspired by the death of then-Vice President Joe Biden’s son, Beau, due to glioblastoma, the NCI launched the Cancer Moonshot in 2016 with the goal of advancing cancer research and treatment.

Age and ethnic background appeared associated with inadequate follow-up care among young adult childhood cancer survivors, according to study results published in JNCI Cancer Spectrum.

The FDA granted orphan drug designation to LP-184 for the treatment of glioblastoma multiforme and other malignant gliomas.

Proton therapy (PT) is a potentially important radiation modality for primary brain tumors due to its unique dose distributions. Unlike photon radiation, PT dose is characterized by a well-defined maximal range where the majority of the dose is deposited, followed by a rapid dose falloff to zero distally within a mere few millimeters.

More than 3 decades after receiving FDA approval, proton beam radiation therapy has failed to find a footing as a go-to treatment for many cancers in the United States.

Neuro-oncologists must grapple daily with precarious brain tumors that are often masked by common symptoms such as a headache or seizure.

The FDA approved belzutifan for treatment of cancers associated with von Hippel-Lindau disease.